Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease
05:22pm, Friday, 30'th Dec 2022
Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths.
House Democrats fault FDA for collaborating improperly with Biogen
09:26am, Friday, 30'th Dec 2022
A new report from House Democrats found that the U.S. Food and Drug Administration inappropriately collaborated with Biogen before approving its Alzheimer's treatment Aduhelm. CNBC's 'Squawk Box' team
12 Stocks Turned $10,000 To $277,126 In 12 Months
08:00am, Friday, 30'th Dec 2022
Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.
House committee questions Biogen drug approval process
12:20am, Friday, 30'th Dec 2022
The FDA's approval process of Biogen's Alzheimer's drug was questioned in a Congressional report released Thursday.
3 Biotech Stocks to Watch Heading Into 2023
02:49pm, Thursday, 29'th Dec 2022
Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.
Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels
01:41pm, Thursday, 29'th Dec 2022
A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Biogen's Lecanemab has a PDUFA date of January 6, 2023; the FDA will announce its pre
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug
01:05pm, Thursday, 29'th Dec 2022
The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was "rife with irregularities
Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know
11:00pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.
Is Biogen's Stock Too Risky to Invest in?
12:45pm, Wednesday, 28'th Dec 2022 The Motley Fool
Even at a discount, investors may be taking on a big risk with Biogen.
The Top Three Stocks Analysts Say To Buy
10:20am, Wednesday, 28'th Dec 2022
The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.
Is Biogen's Stock Too Risky to Invest in?
07:45am, Wednesday, 28'th Dec 2022
Even at a discount, investors may be taking on a big risk with Biogen.
Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma
03:05pm, Friday, 23'rd Dec 2022 Zacks Investment Research
Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.
3 Nasdaq Stocks That Are Up 25% in 3 Months
02:53pm, Friday, 23'rd Dec 2022 The Motley Fool
Should you jump on the bandwagon and buy these surging stocks?
1 Green Flag and 1 Red Flag for Biogen
11:30am, Friday, 23'rd Dec 2022 The Motley Fool
Biogen beat the bear market this year.
